217 related articles for article (PubMed ID: 16272625)
1. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
2. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
5. Introduction to sevelamer hydrochloride and its clinical effects.
Tahara H; Tsujimoto Y; Shoji T; Inaba M; Tabata T; Nishizawa Y
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S2-6. PubMed ID: 16109137
[TBL] [Abstract][Full Text] [Related]
6. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
7. [Control of calcium and phosphate in hemodialysis patients].
Eriguchi R; Takei S; Satou Y
Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
[TBL] [Abstract][Full Text] [Related]
8. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
9. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
11. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
Akatsuka T; Mochizuki T; Koike T
Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
14. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
Fischer D; Cline K; Plone MA; Dillon M; Burke SK; Blair AT
Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
17. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
[TBL] [Abstract][Full Text] [Related]
18. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
